Issues in the management of challenging behaviours of adults with autism spectrum disorder

CNS Drugs

Volumn 25, Issue 7, 2011, Pages 597-606

  Matson, Johnny L ^a   Sipes, Megan ^a   Fodstad, Jill C ^a   Fitzgerald, Mary E ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Aggression; Antipsychotics; Aripiprazole; Autistic disorder; Behavioural disorder therapies; Behavioural disorders; Irritability; Pervasive child development disorders; Pica; Risperidone; Self injurious behaviour

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RISPERIDONE;

AGGRESSION; ANGER; AUTISM; AUTOMUTILATION; BEHAVIOR THERAPY; COGNITIVE THERAPY; DRUG APPROVAL; ENVIRONMENTAL FACTOR; FOOD AND DRUG ADMINISTRATION; HUMAN; PICA; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BEHAVIOR THERAPY; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMBINED MODALITY THERAPY; HUMANS; PIPERAZINES; QUINOLONES; RISPERIDONE;

EID: 79959553854     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11591700-000000000-00000     Document Type: Review

References (67)

1. Matson J. Determining treatment outcomes in early intervention programs for autism spectrum disorders: a critical analysis of measurement issues in learning based interventions. Res Dev Disabil 2007; 28 (2): 207-18 (Pubitemid 46274162)
2. Levy SE, Mandell DS, Schultz CJ. Autism. Lancet 2009; 374 (9701): 1627-38
3. Lin JD, Lin LP, Wu JL. Administrative prevalence of autism spectrum disorders based on national disability registers in Taiwan. J Autism Dev Disord 2009; 3 (1): 269-74
4. Marriage S, Wolverton A, Marriage K. Autism spectrum disorders grown up: a chart review of adult functioning. J Can Acad Child Adolesc Psychiatry 2009; 18 (4): 322-8
5. Newschaffer CJ, Falb MD, Gurney JG. National autism prevalence trends from United States special education data. Pediatrics 2005; 115 (3): e227-81
6. Matson JL, LoVullo SV. Trends and topics in autism spectrum disorders research. Res Autism Spectr Disord 2009; 3 (1): 252-7
7. Emerson E, Bromley J. The form and function of challenging behaviors. J Intellect Disabil Res 1995; 39 (5): 388-98
8. McClean B, Grey I. Modifying challenging behavior and planning positive supports. In: Carr A, OReilly G, Noonan Walsh P, et al., editors. The handbook of intellectual disability and clinical psychology practice. New York (NY): Routledge, 2007: 643-84
9. Emerson E, Kiernan C, Alborz A, et al. The prevalence of challenging behaviors: a total population study. Res Dev Disabil 2001; 22: 77-93 (Pubitemid 32112303)
10. Ben-Itzchak E, Zachor DA. The effects of intellectual functioning and autism severity on outcome of early behavioral intervention for children with autism. Res Dev Disabil 2007; 28 (3): 287-303 (Pubitemid 46330666)
11. McClintock K, Hall S, Oliver C. Risk markers associated with challenging behaviors in people with intellectual disabilities: a meta-analytic study. J Intellect Disabil Res 2003; 47 (6): 405-16 (Pubitemid 37080683)
12. Sigafoos J. Communication development and aberrant behavior in children with developmental disabilities. Educ Train Mental Retard Develop Disabil 2000; 35 (2): 168-76
13. Matson JL. Aggression and tantrums in children with autism: a review of behavioral treatments and maintaining variables. J Ment Health Res Intellect Disabil 2009; 2 (3): 169-87
14. Horner RH, Carr EG, Strain PS, et al. Problem behavior interventions for young children with autism: a research synthesis. J Autism Dev Disord 2002; 32 (5): 423-46 (Pubitemid 37486705)
15. McCarthy J, Hemmings C, Kravariti E, et al. Challenging behaviors and co-morbid psychopathology in adults with intellectual disability and autism spectrum disorders. Res Dev Disabil 2010; 31 (2): 362-6
16. Graetz JE. Autism grows up: opportunities for adults with autism. Disabil Soc 2010; 25 (1): 33-47
17. Sturmey P, Lott JD, Laud RB, et al. Correlates of restraint use in an institutional population: a replication. J Intellectual Disabil Res 2005; 49 (3): 501-6 (Pubitemid 40932403)
18. Lee LC, Harrington RA, Chang JJ, et al. Increased risk of injury in children with developmental disabilities. Res Dev Disabil 2008; 29 (3): 247-55 (Pubitemid 351697656)
19. Herzinger CV, Campbell JM. Comparing functional assessment methodologies: a quantitative synthesis. J Autism Dev Disord 2007; 37 (8): 1430-45 (Pubitemid 47255710)
20. Sturmey P, Seiverling L, Ward-Horner J. Assessment of challenging behaviors in people with autism spectrum disorders. In: Matson JL, editor. Clinical assessment and interventions for autism spectrum disorders. New York (NY): Springer, 2009: 131-64
21. Matson JL, Mahan S, Hess JA, et al. Progression of challenging behaviors in children and adolescents with autism spectrum disorder as measured by the Autism Spectrum Disorders-Problem Behaviors for Children (ASD-PBC). Res Autism Spectr Disord 2010; 4 (3): 400-4
22. Chowdhury M, Benson BA, Hillier A. Changes in restricted repetitive behaviors with age: a study of high-functioning adults with autism spectrum disorders. Res Autism Spectr Disord 2010; 4 (2): 210-6
23. Stigler KA, McDougle CJ. Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am 2008; 17 (4): 739-52
24. Marcus RN, Owen R,Kamen L, et al. A placebo-controlled, fixed dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009; 48 (11): 1110-9
25. Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89 (5): 485-91 (Pubitemid 15104762)
26. Arnold LE, Vitiello B, McDougle C, et al. Parent-defined target symptom responses to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003; 42 (12): 1443-50 (Pubitemid 39585974)
27. Matson JL. Applied behavior analysis for children with autism spectrum disorders. New York (NY): Springer, 2009
28. Neidert PL, Dozier CL, Iwata BA, et al. Behavior analysis in intellectual and developmental disabilities. Psychol Serv 2010; 7 (2): 103-13
29. Weeden M, Ehrhardt K, Poling A. Conspicuous by their absence: studies comparing and combining risperidone and applied behavior analysis to reduce challenging behavior in children with autism. Res Autism Spectr Disord 2009; 3 (4): 905-12
30. Reichow B, Volkmar FR. Social skills interventions for individuals with autism: evaluation for evidence-based practices within a best evidence synthesis framework. J Autism Dev Disord 2010; 40 (2): 149-66
31. Koegel RL, Koegel LK, McNerney EK. Pivotal areas in intervention for autism. J Clin Child Psychol 2001; 30 (1): 19-32 (Pubitemid 33657868)
32. Virués-Ortega J. Applied behavior analytic intervention for autism in early childhood: meta-analysis, meta-regression and dose-response meta-analysis of multiple outcomes. Clin Psychol Rev 2010; 30 (4): 387-99
33. OConner AB, Healy O. Long-term post-intensive behavioral intervention outcomes for five children with autism spectrum disorder. Res Autism Spectr Disord 2010; 4 (4): 594-604
34. Campbell JM. Efficacy of behavioral interventions for reducing problem behavior in persons with autism: a quantitative synthesis of single-subject research. Res Dev Disabil 2003; 24 (2): 120-38 (Pubitemid 36293483)
35. Lang R, Didden R, Machalicek W, et al. Behavioral treatment of chronic skin-picking in individuals with developmental disabilities: a systematic review. Res Dev Disabil 2010; 31 (2): 304-15
36. Hollander E, Phillips AT, Yeh CC. Targeted treatments for symptom domains in child and adolescent autism. Lancet 2003; 362 (9385): 732-4 (Pubitemid 37101074)
37. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002; 41 (8): 921-7 (Pubitemid 38338071)
38. West L, Waldrop J, Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009; 23 (2): 75-89
39. Canitano R, Scandurra V. Psychopharmacology in autism: an update. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35 (1): 18-28
40. Aman MG, Van Bourgondien M, Wolford PL, et al. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry 1995; 34 (12): 1672-81
41. Martin A, Scahill L, Klin A, et al. High-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 1999; 38 (7): 923-31 (Pubitemid 29309854)
42. Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism. Child Adolesc Psychiatr Clin N Am 2008; 17 (4): 787-801
43. Mahan S, Holloway J, Bamburg JW, et al. An examination of psychotropic medication side effects: does taking a greater number of psychotropic medications from different classes affect presentation of side effects in adults with ID? Res Dev Disabil 2010; 31 (6): 1561-9
44. McDougle CJ, Stigler KA, Erickson CA, et al. Pharmacology of autism. Clin Neurosci Res 2006; 6 (3-4): 179-88 (Pubitemid 44567518)
45. Deokar AM, Huff M, Omar HA. Clinical management of adolescents with autism. Pediatr Clin North Am 2008; 55 (5): 1147-57
46. McDougle CJ, Brodkin ES, Yeung PP, et al. Risperidone in adults with autism or pervasive developmental disorders. J Child Adolesc Psychopharmacol 1995; 5 (4): 273-82 (Pubitemid 26068363)
47. McDougle CJ, Holmes JP, Carlson RC, et al. A doubleblind placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998; 55 (7): 633-41 (Pubitemid 28340352)
48. Potenza MN, Holmes JP, Kanes SJ, et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Child Adolesc Psychopharmacol 1999; 19 (1): 37-44 (Pubitemid 29047329)
49. Oliver-Africano P, Murphy D, Tyrer P. Aggressive behaviors in adults with intellectual disability: defining the role of drug treatment. CNS Drugs 2009; 23 (11): 903-13
50. Remington G, Sloman L, Konstantareas M, et al. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol 2001; 21 (4): 440-4 (Pubitemid 32673034)
51. Cook EH, Rowlett R, Jaselskis C, et al. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. JAmAcad Child Adolesc Psychiatry 1992; 31 (4): 739-45
52. Iwata BA, Dorsey MF, Slifer KJ, et al. Toward a function analysis of self-injury. Anal Intervention Dev Disabil 1982; 2 (1): 3-20
53. Matson JL, Vollmer TR. Questions about behavioral functioning [online]. Available from URL: http://www.disabil ityconsultants.org [Accessed 2011 May 4]
54. Matson JL, Bamburg JW, Cherry KE. A validity study on the Questions About Behavioral Function (QABF) Scale: predicting treatment success for self-injury, aggression, and stereotypies. Res Dev Disabil 1999; 20 (2): 163-76 (Pubitemid 29153702)
55. Hellings JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 2001; 11 (3): 229-38 (Pubitemid 32937635)
56. Matson JL. Matson Evaluation of Drug Side-effects (MEDS). Baton Rouge (LA): Disability Consultants, LLC
57. Advocate CD, Mayville EA, Matson JL. Side effects of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation. Res Dev Disabil 2000; 21 (1): 75-84 (Pubitemid 30133370)
58. Holden B, Gitlesen JP. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. Res Dev Disabil 2004; 25: 509-21 (Pubitemid 39486038)
59. Handen BL, Lubetsky M. Pharmacotherapy in autism and related disorders. Sch Psychol Q 2005; 20 (2): 155-71 (Pubitemid 40979568)
60. Howlin P. Interventions and outcomes in autism. In: Singh NN, Ollendick TH, Singh AN, editors. International perspectives on child and adolescent mental health. Vol. 2. San Diego (CA): Elsevier Science, 2002: 69-99
61. Bradley E, Bolton P. Episodic psychiatric disorders in teenagers with learning disabilities with and without autism. Br J Psychiatry 2006; 189: 361-6 (Pubitemid 44606750)
62. Eaves LC, Ho HH. Young adult outcome of autism spectrum disorders. J Autism Dev Disord 2008; 38 (4): 739-47 (Pubitemid 351421888)
63. King BH, Bostic JQ. An update on pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2006; 15 (1): 161-75
64. Nevels RM, Dehon EE, Alexander K, et al. Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol 2010; 18 (2): 184-201
65. Hollander E, Soorya L, Wasserman S, et al. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. J Neuropsychopaharmacology 2005; 9 (2): 209-13
66. Potkin SG, Gharabawi GM, Greenspan AJ, et al. A doubleblind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006; 85 (1): 254-6
67. Malone RP, Maislin G, Chondhury MS, et al. Risperidone treatment in children and adolescents with autism: shortand long-term safety and effectiveness. J Am Acad Child Psychiatry 2002; 41 (2): 140-7 (Pubitemid 38338162)